LimJY personal page - To The Moon

LimJY

LimJY

No personal profile

4Follow

2Followers

0Topic

0Badge

2021-09-14

This is a refreshing take on things!

Here are two large tech stocks to avoid, according to Goldman Sachs

2021-08-27

Interesting read!

Who Owns The Most AMC Stock?

2021-08-21

Ooooooh...

Here's What Recent News From the FDA Means for AstraZeneca

2021-08-19

Uh-oh...

Sorry, the original content has been removed

2021-08-13

Hang in there! ??

Biden Economic Agenda Confronts Tripwires Everywhere in Congress

2021-08-11

Go, Wendy's! Love your spicy fried chicken! ?

Wendy's beats U.S. same-store sales estimates

2021-07-31

Interesting...

Wall Street declines with Amazon; S&P 500 posts gains for month

2021-07-30

):

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3585355301358956","uuid":"3585355301358956","gmtCreate":1627435412679,"gmtModify":1704447509471,"name":"LimJY","pinyin":"limjy","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":4,"tweetSize":32,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","exceedPercentage":"60.42%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":886223594,"gmtCreate":1631597007718,"gmtModify":1676530585842,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585355301358956","idStr":"3585355301358956"},"themes":[],"htmlText":"This is a refreshing take on things!&nbsp;","listText":"This is a refreshing take on things!&nbsp;","text":"This is a refreshing take on things!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/886223594","repostId":"1141290411","repostType":4,"repost":{"id":"1141290411","kind":"news","pubTimestamp":1631591077,"share":"https://ttm.financial/m/news/1141290411?lang=&edition=fundamental","pubTime":"2021-09-14 11:44","market":"us","language":"en","title":"Here are two large tech stocks to avoid, according to Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=1141290411","media":"Marketwatch","summary":"There’s still some opportunity among large-cap internet stocks, but investors should steer clear of ","content":"<p>There’s still some opportunity among large-cap internet stocks, but investors should steer clear of two names, according to Goldman Sachs.</p>\n<p>Goldman’s Eric Sheridan initiated coverage of 17 larger-capitalization internet stocks late Sunday and assigned sell ratings to Airbnb Inc.ABNBand Twitter Inc.TWTRshares. Airbnb’s stock is off 2.8% in Monday trading, while Twitter’s is down 3.4%.</p>\n<p>While Sheridan expects that Airbnb will continue to outgrow the broader online travel industry over the next five years, he sees a negative risk-reward balance on the stock.</p>\n<p>Sheridan wrote that investors seem to have high conviction that Airbnb will benefit from a “new normal” for travel given the emergence of more flexible work/life structures, meaning that they would be able to travel more freely and spend more time at their destinations. But he’s “not yet convinced of that outcome having a high probability” and argues that significant investor optimism about this dynamic is already priced into Airbnb’s stock.</p>\n<p>He set a $132 price target on the stock, which changed hands just above $160 as of midday Monday.</p>\n<p>Sheridan also worries about the risk/reward trade-off on Twitter, writing that he thinks the advertising recovery is priced into the shares.</p>\n<p>Another key issue for Twitter is whether the company can successfully use new features like audio rooms, newsletters, and tip jars to boost engagement and monetization. Twitter has been increasing the pace of feature introductions recently after gaining a reputation for being slow on innovation, but “the probability of success of these platform evolutions remains an open question,” Sheridan wrote.</p>\n<p>He set a $60 price target for the stock, which recently changed hands at $59.44.</p>\n<p>Sheridan was more upbeat on other elements of the internet universe, assigning buy ratings to shares of Amazon.com Inc.&nbsp;,Facebook Inc.&nbsp;,Alphabet Inc.&nbsp;,Snap Inc.&nbsp;,Uber Technologies Inc.&nbsp;,Lyft Inc.&nbsp;,and Expedia Group Inc.</p>\n<p>He is neutral on shares of Pinterest Inc.&nbsp;,Chewy Inc.&nbsp;,Netflix Inc.&nbsp;,Peloton Interactive Inc.&nbsp;,Spotify Technology,Booking Holdings Inc.&nbsp;,and DoorDash Inc.&nbsp;</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here are two large tech stocks to avoid, according to Goldman Sachs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere are two large tech stocks to avoid, according to Goldman Sachs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-14 11:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/here-are-two-large-tech-stocks-to-avoid-according-to-goldman-sachs-11631550925?mod=newsviewer_click><strong>Marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There’s still some opportunity among large-cap internet stocks, but investors should steer clear of two names, according to Goldman Sachs.\nGoldman’s Eric Sheridan initiated coverage of 17 larger-...</p>\n\n<a href=\"https://www.marketwatch.com/story/here-are-two-large-tech-stocks-to-avoid-according-to-goldman-sachs-11631550925?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABNB":"爱彼迎","TWTR":"Twitter"},"source_url":"https://www.marketwatch.com/story/here-are-two-large-tech-stocks-to-avoid-according-to-goldman-sachs-11631550925?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1141290411","content_text":"There’s still some opportunity among large-cap internet stocks, but investors should steer clear of two names, according to Goldman Sachs.\nGoldman’s Eric Sheridan initiated coverage of 17 larger-capitalization internet stocks late Sunday and assigned sell ratings to Airbnb Inc.ABNBand Twitter Inc.TWTRshares. Airbnb’s stock is off 2.8% in Monday trading, while Twitter’s is down 3.4%.\nWhile Sheridan expects that Airbnb will continue to outgrow the broader online travel industry over the next five years, he sees a negative risk-reward balance on the stock.\nSheridan wrote that investors seem to have high conviction that Airbnb will benefit from a “new normal” for travel given the emergence of more flexible work/life structures, meaning that they would be able to travel more freely and spend more time at their destinations. But he’s “not yet convinced of that outcome having a high probability” and argues that significant investor optimism about this dynamic is already priced into Airbnb’s stock.\nHe set a $132 price target on the stock, which changed hands just above $160 as of midday Monday.\nSheridan also worries about the risk/reward trade-off on Twitter, writing that he thinks the advertising recovery is priced into the shares.\nAnother key issue for Twitter is whether the company can successfully use new features like audio rooms, newsletters, and tip jars to boost engagement and monetization. Twitter has been increasing the pace of feature introductions recently after gaining a reputation for being slow on innovation, but “the probability of success of these platform evolutions remains an open question,” Sheridan wrote.\nHe set a $60 price target for the stock, which recently changed hands at $59.44.\nSheridan was more upbeat on other elements of the internet universe, assigning buy ratings to shares of Amazon.com Inc. ,Facebook Inc. ,Alphabet Inc. ,Snap Inc. ,Uber Technologies Inc. ,Lyft Inc. ,and Expedia Group Inc.\nHe is neutral on shares of Pinterest Inc. ,Chewy Inc. ,Netflix Inc. ,Peloton Interactive Inc. ,Spotify Technology,Booking Holdings Inc. ,and DoorDash Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819351320,"gmtCreate":1630036862660,"gmtModify":1676530207284,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585355301358956","idStr":"3585355301358956"},"themes":[],"htmlText":"Interesting read!","listText":"Interesting read!","text":"Interesting read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819351320","repostId":"1196717589","repostType":4,"repost":{"id":"1196717589","kind":"news","pubTimestamp":1630034074,"share":"https://ttm.financial/m/news/1196717589?lang=&edition=fundamental","pubTime":"2021-08-27 11:14","market":"us","language":"en","title":"Who Owns The Most AMC Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=1196717589","media":"Thestreet","summary":"Of all the things to consider before buying a stock, understanding who owns the company’s equity is ","content":"<p>Of all the things to consider before buying a stock, understanding who owns the company’s equity is rarely a top-of-mind factor. In the case of AMC, however, the story may be a little different.</p>\n<p>Today, Wall Street Memes looks at AMC stock’s ownership and explains why it could have an impact on how the company operates – and how the stock behaves.</p>\n<p><b>AMC largest holders</b></p>\n<p>According to data provided byYahoo Finance, AMC has a float of 513 million shares. Of the total, about 74% is owned by the public, 25% by institutions and 0.3% by insiders – directors, company's officers, and those with access to company information before it becomes public.</p>\n<p>Among institutions, Vanguard and Blackrock are the top holders, with 8% and 6% of the shares, respectively. Naturally, these firms turn their holdings into shares of ETF, which in turn can (and usually do) end up owned by more individual investors.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/03a5fac491fbf01869bb0f43310b2bc9\" tg-width=\"1200\" tg-height=\"966\" referrerpolicy=\"no-referrer\"><span>Figure 1: AMC stock ownership.ChartMill</span></p>\n<p>In May, AMC's previous largest shareholder, China's Dalian Wanda Group Co,sold30.4 million of its shares purchased in 2012 for roughly $430 million – funny enough, only days before AMC stock spiked from $14 to over $60 apiece. Currently, Wanda owns only 10,000 shares, representing a small $420,000 in market value.</p>\n<p>After the large Wanda sale, AMC's CEO Adam Aronrevealedthat no entity held an ownership stake above 10%.</p>\n<h3>Implications for the stock</h3>\n<p>A company whose ownership is widely distributed across the general public, as is the case of AMC, can benefit in a couple of ways. For instance, AMC can implement or change company policy without necessarily being aligned first with a handful of key shareholders.</p>\n<p>AMC’s ownership layout allowed for something curious to happen recently. CEO Adam Aron put to a vote theissuanceof 25 million new shares, which was then vetoed by a majority of AMC shareholders due to fears over a share price decline. Were AMC primarily owned by only a few, the polling would have likely not even taken place.</p>\n<p>In the end, the ownership structure allows AMC the flexibility to make its strategic decisions with certain independence – unless the management team chooses to consult with the broader base of individual investors more often.</p>\n<h3>In conclusion</h3>\n<p>AMC stock is owned, by and large, by retail investors – roughly speaking, the AMC ape community. Based on the latest shareholder count&nbsp;providedby AMC itself, the percentage of general public ownership is now greater than 80%, with each retail investor holding around 120 shares ($5,000) on average.</p>\n<p>Wall Street Memes believes that this is a good setup for AMC’s retail investors, as the fate of the company depends much less on the agenda of large institutions and a few insiders.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Who Owns The Most AMC Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWho Owns The Most AMC Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 11:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/amc/who-owns-the-most-amc-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Of all the things to consider before buying a stock, understanding who owns the company’s equity is rarely a top-of-mind factor. In the case of AMC, however, the story may be a little different.\nToday...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/amc/who-owns-the-most-amc-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.thestreet.com/memestocks/amc/who-owns-the-most-amc-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196717589","content_text":"Of all the things to consider before buying a stock, understanding who owns the company’s equity is rarely a top-of-mind factor. In the case of AMC, however, the story may be a little different.\nToday, Wall Street Memes looks at AMC stock’s ownership and explains why it could have an impact on how the company operates – and how the stock behaves.\nAMC largest holders\nAccording to data provided byYahoo Finance, AMC has a float of 513 million shares. Of the total, about 74% is owned by the public, 25% by institutions and 0.3% by insiders – directors, company's officers, and those with access to company information before it becomes public.\nAmong institutions, Vanguard and Blackrock are the top holders, with 8% and 6% of the shares, respectively. Naturally, these firms turn their holdings into shares of ETF, which in turn can (and usually do) end up owned by more individual investors.\nFigure 1: AMC stock ownership.ChartMill\nIn May, AMC's previous largest shareholder, China's Dalian Wanda Group Co,sold30.4 million of its shares purchased in 2012 for roughly $430 million – funny enough, only days before AMC stock spiked from $14 to over $60 apiece. Currently, Wanda owns only 10,000 shares, representing a small $420,000 in market value.\nAfter the large Wanda sale, AMC's CEO Adam Aronrevealedthat no entity held an ownership stake above 10%.\nImplications for the stock\nA company whose ownership is widely distributed across the general public, as is the case of AMC, can benefit in a couple of ways. For instance, AMC can implement or change company policy without necessarily being aligned first with a handful of key shareholders.\nAMC’s ownership layout allowed for something curious to happen recently. CEO Adam Aron put to a vote theissuanceof 25 million new shares, which was then vetoed by a majority of AMC shareholders due to fears over a share price decline. Were AMC primarily owned by only a few, the polling would have likely not even taken place.\nIn the end, the ownership structure allows AMC the flexibility to make its strategic decisions with certain independence – unless the management team chooses to consult with the broader base of individual investors more often.\nIn conclusion\nAMC stock is owned, by and large, by retail investors – roughly speaking, the AMC ape community. Based on the latest shareholder count providedby AMC itself, the percentage of general public ownership is now greater than 80%, with each retail investor holding around 120 shares ($5,000) on average.\nWall Street Memes believes that this is a good setup for AMC’s retail investors, as the fate of the company depends much less on the agenda of large institutions and a few insiders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836412336,"gmtCreate":1629513985825,"gmtModify":1676530062934,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585355301358956","idStr":"3585355301358956"},"themes":[],"htmlText":"Ooooooh...","listText":"Ooooooh...","text":"Ooooooh...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836412336","repostId":"2160714914","repostType":4,"repost":{"id":"2160714914","kind":"highlight","pubTimestamp":1629464330,"share":"https://ttm.financial/m/news/2160714914?lang=&edition=fundamental","pubTime":"2021-08-20 20:58","market":"us","language":"en","title":"Here's What Recent News From the FDA Means for AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=2160714914","media":"Motley Fool","summary":"Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost.","content":"<p>Last month, the <a href=\"https://laohu8.com/S/CSII\">Cardiovascular</a> and Renal Drugs Advisory Committee (CRDAC) of the U.S. Food and Drug Administration (FDA) denied <b><a href=\"https://laohu8.com/S/AZN\">AstraZeneca PLC</a> </b>(NASDAQ:&nbsp;AZN) and <b><a href=\"https://laohu8.com/S/FGEN\">FibroGen</a></b>'s (NASDAQ:&nbsp;FGEN) drug roxadustat for the treatment of anemia in patients with chronic kidney disease (CKD).</p>\n<p>This was in both non-dialysis-dependent (NDD) patients (by a 13-to-1 vote) and dialysis-dependent (DD) patients (a 12-to-2 vote).</p>\n<p>AstraZeneca and FibroGen are collaborating to develop and commercialize roxadustat for the treatment of anemia related to CKD in areas including the U.S., Australia and <a href=\"https://laohu8.com/S/NGD\">New</a> Zealand, <a href=\"https://laohu8.com/S/CAAS\">China</a>, and Southeast Asia. Meanwhile, FibroGen and <b><a href=\"https://laohu8.com/S/ALPMY\">Astellas Pharma, Inc.</a> </b>(OTC:&nbsp;ALPMY) are developing and commercializing roxadustat for the treatment of CKD-related anemia in Japan, Europe, the Middle East, and South Africa.</p>\n<p>AstraZeneca and FibroGen received a complete response letter from the FDA earlier this month, requesting another safety trial for both the NDD and DD patient populations. Let's break down the implications for roxadustat's future, and what that might mean for AstraZeneca.</p>\n<p><img src=\"https://static.tigerbbs.com/bb06b77b879f31a4dff027154b6d049e\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h2>The logic behind the panel's decision</h2>\n<p>It's worth discussing what led to this decisive rejection. While FDA staffer Dr. Saleh Ayache noted that \"the FDA believes the Applicant has provided substantial evidence of efficacy,\" CRDAC chair Dr. Julia Lewis indicated that \"there are concerns over adverse safety.\"</p>\n<p>To this point, FibroGen announced in April that the disclosed safety analyses for roxadustat from November 2019 in the treatment of anemia of CKD were incorrect.</p>\n<p>In the original presentation of the study's data, the risk of non-dialysis-dependent (NDD) patients taking roxadustat and experiencing major adverse cardiac events (MACE) over the duration of the Phase 3 trial was 8% higher than for patients taking placebo. The revised data showed a slight increase in that risk, to 10% more than placebo, adding to the overall risk profile of the drug and working against the odds of a potential FDA approval.</p>\n<p>The risk of dialysis-dependent (DD) patients taking roxadustat and suffering from MACE was initially thought to be 4% lower than for those taking peer drug epoetin-alfa (Epogen, developed by <b><a href=\"https://laohu8.com/S/AMGN\">Amgen</a></b> and <b>Johnson and Johnson</b>). However, the revised data showed that the probability of DD patients taking roxadustat and enduring MACE was actually 2% higher than Epogen. This meant that AstraZeneca and FibroGen were no longer able to claim that roxadustat was safer than Epogen in DD patients, which was a claim that previously gave roxadustat an advantage over Epogen.</p>\n<p>The risk of incident dialysis (ID) patients who have been on dialysis for four months or less taking roxadustat and experiencing MACE was initially thought to be 30% lower compared to Epogen, but the corrected data showed that the risk of MACE complications was only reduced by 18%. While roxadustat remains safer than Epogen in ID patients, the advantage is far less than what was thought to be the case initially.</p>\n<p>AstraZeneca and FibroGen will now consider funding an additional clinical trial to continue pursuing FDA approval for roxadustat to treat CKD-related anemia. The trial would test whether a lower dosage of roxadustat would improve its safety profile, possibly allowing FDA approval later down the road assuming efficacy remained steady.</p>\n<h2>Roxadustat is down, but not out</h2>\n<p>Even with CRDAC's request for another clinical trial, there's reason to be optimistic. Roxadustat was approved by China's <a href=\"https://laohu8.com/S/NHLD\">National</a> Medical Products Administration (NMPA) to be marketed for treating anemia in CKD patients, both on dialysis and not on dialysis, in August 2019. And while roxadustat has been on the market in China for less than two years, the drug has made a great deal of progress in the country during that time.</p>\n<p>According to FibroGen, hospital listings (a list or formulary of all the drugs available for prescription from a particular hospital) at the end of the second quarter of 2021 \"represented approximately 81% of the CKD anemia market opportunity in China,\" compared with 74% in the prior quarter. In other words, hospital offerings of the drug in China continue to expand. Roxadustat's continued penetration in the China market generated $92 million in revenue for AstraZeneca during the first half of 2021, with an acceleration from $40 million in Q1 to $52 million in <a href=\"https://laohu8.com/S/QTWO\">Q2</a>.</p>\n<p>Even if AstraZeneca isn't ultimately able to secure FDA approval to treat the 6 million patients in the <a href=\"https://laohu8.com/S/UBNK\">United</a> States with anemia related to CKD, the Chinese market alone could be enough to more than double sales of the drug from now till the end of the decade.</p>\n<p>This is supported by a combination of growing adoption of roxadustat within China, as well as the fact that Research and Markets expects the CKD anemia market to grow 3.4% annually, to reach global sales of $6.6 billion by 2029.</p>\n<p>The research company anticipates that the Chinese market alone will reach $1 billion in revenue by 2029, so I can see a clear path to about $400 million by the end of the decade for AstraZeneca.</p>\n<h2>AstraZeneca will be fine regardless of FDA approval</h2>\n<p>While it remains to be seen whether roxadustat will someday be approved by the FDA, AstraZeneca isn't depending on the approval as much as FibroGen.</p>\n<p>This is because unlike FibroGen, which is highly dependent on roxadustat (all of its product revenue came from roxadustat in the first half of this year), AstraZeneca is a diversified large-cap pharma company.</p>\n<p>AstraZeneca owns three rapidly growing oncology drugs (Tagrisso, Imfinzi, and Lynparza), which grew their total first-half revenue 25.3% year over year from $3.79 billion in H1 2020 to $4.75 billion in H1 2021.</p>\n<p>AstraZeneca's completed acquisition of <a href=\"https://laohu8.com/S/ALXN\">Alexion Pharmaceuticals</a> last month only further solidified the company's growth potential. That's because Alexion's top three drugs (Soliris, Ultomiris, and Strensiq) saw their net revenue soar 20.4% from $4.88 billion in 2019 to $5.87 billion in 2020.</p>\n<p>AstraZeneca is trading at around 16 times next year's average analyst EPS (earnings per share) estimate of $3.71, which is still a solid value, given the 20% annual earnings growth that analysts expect over the next five years.</p>\n<p>Those who already own AstraZeneca and those considering adding it to their portfolios can both be confident that the company's future is solid regardless of roxadustat's U.S. status.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's What Recent News From the FDA Means for AstraZeneca</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's What Recent News From the FDA Means for AstraZeneca\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 20:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/20/heres-what-recent-fda-news-means-for-astrazeneca/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last month, the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) of the U.S. Food and Drug Administration (FDA) denied AstraZeneca PLC (NASDAQ: AZN) and FibroGen's (NASDAQ: FGEN) drug ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/20/heres-what-recent-fda-news-means-for-astrazeneca/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","FGEN":"FibroGen, Inc","ALPMY":"Astellas Pharma, Inc."},"source_url":"https://www.fool.com/investing/2021/08/20/heres-what-recent-fda-news-means-for-astrazeneca/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160714914","content_text":"Last month, the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) of the U.S. Food and Drug Administration (FDA) denied AstraZeneca PLC (NASDAQ: AZN) and FibroGen's (NASDAQ: FGEN) drug roxadustat for the treatment of anemia in patients with chronic kidney disease (CKD).\nThis was in both non-dialysis-dependent (NDD) patients (by a 13-to-1 vote) and dialysis-dependent (DD) patients (a 12-to-2 vote).\nAstraZeneca and FibroGen are collaborating to develop and commercialize roxadustat for the treatment of anemia related to CKD in areas including the U.S., Australia and New Zealand, China, and Southeast Asia. Meanwhile, FibroGen and Astellas Pharma, Inc. (OTC: ALPMY) are developing and commercializing roxadustat for the treatment of CKD-related anemia in Japan, Europe, the Middle East, and South Africa.\nAstraZeneca and FibroGen received a complete response letter from the FDA earlier this month, requesting another safety trial for both the NDD and DD patient populations. Let's break down the implications for roxadustat's future, and what that might mean for AstraZeneca.\n\nImage source: Getty Images.\nThe logic behind the panel's decision\nIt's worth discussing what led to this decisive rejection. While FDA staffer Dr. Saleh Ayache noted that \"the FDA believes the Applicant has provided substantial evidence of efficacy,\" CRDAC chair Dr. Julia Lewis indicated that \"there are concerns over adverse safety.\"\nTo this point, FibroGen announced in April that the disclosed safety analyses for roxadustat from November 2019 in the treatment of anemia of CKD were incorrect.\nIn the original presentation of the study's data, the risk of non-dialysis-dependent (NDD) patients taking roxadustat and experiencing major adverse cardiac events (MACE) over the duration of the Phase 3 trial was 8% higher than for patients taking placebo. The revised data showed a slight increase in that risk, to 10% more than placebo, adding to the overall risk profile of the drug and working against the odds of a potential FDA approval.\nThe risk of dialysis-dependent (DD) patients taking roxadustat and suffering from MACE was initially thought to be 4% lower than for those taking peer drug epoetin-alfa (Epogen, developed by Amgen and Johnson and Johnson). However, the revised data showed that the probability of DD patients taking roxadustat and enduring MACE was actually 2% higher than Epogen. This meant that AstraZeneca and FibroGen were no longer able to claim that roxadustat was safer than Epogen in DD patients, which was a claim that previously gave roxadustat an advantage over Epogen.\nThe risk of incident dialysis (ID) patients who have been on dialysis for four months or less taking roxadustat and experiencing MACE was initially thought to be 30% lower compared to Epogen, but the corrected data showed that the risk of MACE complications was only reduced by 18%. While roxadustat remains safer than Epogen in ID patients, the advantage is far less than what was thought to be the case initially.\nAstraZeneca and FibroGen will now consider funding an additional clinical trial to continue pursuing FDA approval for roxadustat to treat CKD-related anemia. The trial would test whether a lower dosage of roxadustat would improve its safety profile, possibly allowing FDA approval later down the road assuming efficacy remained steady.\nRoxadustat is down, but not out\nEven with CRDAC's request for another clinical trial, there's reason to be optimistic. Roxadustat was approved by China's National Medical Products Administration (NMPA) to be marketed for treating anemia in CKD patients, both on dialysis and not on dialysis, in August 2019. And while roxadustat has been on the market in China for less than two years, the drug has made a great deal of progress in the country during that time.\nAccording to FibroGen, hospital listings (a list or formulary of all the drugs available for prescription from a particular hospital) at the end of the second quarter of 2021 \"represented approximately 81% of the CKD anemia market opportunity in China,\" compared with 74% in the prior quarter. In other words, hospital offerings of the drug in China continue to expand. Roxadustat's continued penetration in the China market generated $92 million in revenue for AstraZeneca during the first half of 2021, with an acceleration from $40 million in Q1 to $52 million in Q2.\nEven if AstraZeneca isn't ultimately able to secure FDA approval to treat the 6 million patients in the United States with anemia related to CKD, the Chinese market alone could be enough to more than double sales of the drug from now till the end of the decade.\nThis is supported by a combination of growing adoption of roxadustat within China, as well as the fact that Research and Markets expects the CKD anemia market to grow 3.4% annually, to reach global sales of $6.6 billion by 2029.\nThe research company anticipates that the Chinese market alone will reach $1 billion in revenue by 2029, so I can see a clear path to about $400 million by the end of the decade for AstraZeneca.\nAstraZeneca will be fine regardless of FDA approval\nWhile it remains to be seen whether roxadustat will someday be approved by the FDA, AstraZeneca isn't depending on the approval as much as FibroGen.\nThis is because unlike FibroGen, which is highly dependent on roxadustat (all of its product revenue came from roxadustat in the first half of this year), AstraZeneca is a diversified large-cap pharma company.\nAstraZeneca owns three rapidly growing oncology drugs (Tagrisso, Imfinzi, and Lynparza), which grew their total first-half revenue 25.3% year over year from $3.79 billion in H1 2020 to $4.75 billion in H1 2021.\nAstraZeneca's completed acquisition of Alexion Pharmaceuticals last month only further solidified the company's growth potential. That's because Alexion's top three drugs (Soliris, Ultomiris, and Strensiq) saw their net revenue soar 20.4% from $4.88 billion in 2019 to $5.87 billion in 2020.\nAstraZeneca is trading at around 16 times next year's average analyst EPS (earnings per share) estimate of $3.71, which is still a solid value, given the 20% annual earnings growth that analysts expect over the next five years.\nThose who already own AstraZeneca and those considering adding it to their portfolios can both be confident that the company's future is solid regardless of roxadustat's U.S. status.","news_type":1},"isVote":1,"tweetType":1,"viewCount":380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831435376,"gmtCreate":1629339745095,"gmtModify":1676530008058,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585355301358956","idStr":"3585355301358956"},"themes":[],"htmlText":"Uh-oh...","listText":"Uh-oh...","text":"Uh-oh...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831435376","repostId":"1129521206","repostType":4,"isVote":1,"tweetType":1,"viewCount":435,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894695728,"gmtCreate":1628820174064,"gmtModify":1676529865156,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585355301358956","idStr":"3585355301358956"},"themes":[],"htmlText":"Hang in there! ??","listText":"Hang in there! ??","text":"Hang in there! ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894695728","repostId":"1154636497","repostType":4,"repost":{"id":"1154636497","kind":"news","pubTimestamp":1628816538,"share":"https://ttm.financial/m/news/1154636497?lang=&edition=fundamental","pubTime":"2021-08-13 09:02","market":"us","language":"en","title":"Biden Economic Agenda Confronts Tripwires Everywhere in Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=1154636497","media":"Bloomberg","summary":"Debt ceiling, funding deadline complicates path after break\nDemocrats aim for early fall completion,","content":"<ul>\n <li>Debt ceiling, funding deadline complicates path after break</li>\n <li>Democrats aim for early fall completion, but obstacles await</li>\n</ul>\n<p>The central pieces of President Joe Biden’s $4.1 trillion economic agenda are now moving through Congress on a precarious two-track path that’s further complicated by a September showdown over the debt ceiling.</p>\n<p>Funding for the government will expire and the Treasury will approach the limit of its borrowing authority just as congressional Democrats try to make the administration’s massive infrastructure and social spending plans a reality.</p>\n<p>The convergence will test the limits of how well House Speaker Nancy Pelosi and Senator Majority Leader Chuck Schumer can manage their narrow -- and often fractious -- majorities and Biden’s ability to bargain with dissenters.</p>\n<p>The first part of Biden’s plan, infrastructure legislation with $550 billion in new spending, passed the Senate on a bipartisan basis. But the framework for a much larger plan -- a $3.5 trillion budget resolution opening the way to expansive spending on social programs paid for in part by taxes on the wealthy and corporations -- squeaked through on a straight party-line vote.</p>\n<p>Here’s what’s ahead for a process that could last through year-end:</p>\n<p>House Vote</p>\n<p>Pelosi is briefly interrupting the chamber’s summer recess by calling lawmakers back to <a href=\"https://laohu8.com/S/WASH\">Washington</a> on Aug. 23 to vote on the Senate’s budget resolution.</p>\n<p>She needs near-unanimous Democratic support to adopt it against anticipated unified GOP opposition. The resolution is just an outline setting the parameters for an eventual budget bill and instructions for committees to draw up legislative text. It doesn’t require the president’s signature.</p>\n<p>For now, the infrastructure bill is on hold. In a bow to demands by House progressives, Pelosi has vowed to wait until the Senate finishes the budget package to assure it addresses priorities on social programs and climate change. House Democrats may also want changes to the carefully negotiated infrastructure legislation.</p>\n<p>Committee Work</p>\n<p>Both chambers will then move to write precise policies and other language for the massive budget package, with the House likely to go first, predicts Zach Moller, a former Democratic Senate staffer who now works for Third Way, a centrist policy-research organization.</p>\n<p>House Democrats, ranging from top Pelosi lieutenants and powerful committee chairs to upstart progressives, are already signaling various changes they want to see in a final version of the Senate’s reconciliation package.</p>\n<p>The Senate-passed resolution sets a nonbinding Sept. 15 deadline for committees in both chambers to submit proposals to their respective budget panels.</p>\n<p>The Senate Finance Committee has jurisdiction over the heart of the package, including the tax hikes on the wealthy and corporations. Other committees can increase the deficit by about $1.75 trillion combined over a decade -- meaningup tohalf of Biden’s plan could be debt-financed.</p>\n<p>There is no firm deadline on passage of the economic agenda, but Democrats keen on keeping their congressional majorities in the November 2022 midterm elections want the packages enacted this fall. That would allow voters time tofeelthe legislation’s effects and provide for the extension of popular pandemic-era benefits like the expanded child tax credit, which would otherwise end in December.</p>\n<p>Funding Showdown</p>\n<p>By Sept. 30, lawmakers must reach bipartisan deals on unfinished regular government spending bills or on a stopgap bill to keep agencies running that would maintain current spending levels through at least October or early November.</p>\n<p>Such a measure could carry language temporarily suspending the debt limit. But doing so could trigger a government shutdown. Republicans say Democrats must go it alone on the debt ceiling and want them to revise the budget resolution to allow them to pass a hike with a simple majority.</p>\n<p>Senate Democrats, however, insist for now on using the regular legislative process, which would require at least 10 Republicans to join them. Prospects for a bitter battle this fall have alreadystarted to impact short-term debt markets.</p>\n<p>Hazards Ahead</p>\n<p>Obstacles abound in the coming months. For <a href=\"https://laohu8.com/S/AONE.U\">one</a>, House Democrats can afford just three defectors in a party-line vote. In the evenly divided Senate, unity is the only option.</p>\n<p>Even the House’s vote this month on the budget framework is no slam dunk. Party moderates, who want an immediate vote on the infrastructure package, could withhold their backing, stalling the measure.</p>\n<p>In the Senate, not all Democrats are on board with the $3.5 trillion package, even though they all voted for the framework. Some, like Kyrsten Sinema of Arizona and Joe Manchin of <a href=\"https://laohu8.com/S/WSTC\">West</a> Virginia, say they’re uncomfortable with the price tag or the size of the tax hikes Biden has proposed to help pay for it.</p>\n<p>Manchin has also said he disagrees with Democrats who want to target fossil fuels -- setting up tension for a key piece of the legislation.</p>\n<p>Schumer asserted Wednesday Democrats would ultimately unite, but he acknowledged it wouldn’t be easy.</p>\n<p>Republicans will have ample opportunity to split Democrats and make their case that more taxes and spending will increase inflation and hurt the economy. Under special Senate rules they can force nearly unlimited amendments trying to strike individual provisions, potentially peeling off some Democrats in politically fraught votes.</p>\n<p>Procedural Pitfalls</p>\n<p>The package will still have to clear a major procedural hurdle scrubbing it of anything deemed incidental to the federal budget.</p>\n<p>Biden’s $1.9 trillion Covid-19 relief package was shorn of a proposal for a $15-an-hour minimum wage via that process. Potential challenges in the $3.5 trillion plan include providing a path to citizenship for millions of immigrants.</p>\n<p>All of this comes with long-term implications. In the short term, any misstep -- particularly on government spending and the debt ceiling -- could have large-scale reverberations in the market and the broader economy.</p>\n<p>“I am one who believes that neither party wins with government shut down or certainly government default so I lean toward being a little more optimistic that the latter will be avoided,” said former Senate Budget Committee Republican staff director Bill Hoagland, who’s now at the Bipartisan Policy Center. “But this is really an uncertain time.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biden Economic Agenda Confronts Tripwires Everywhere in Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiden Economic Agenda Confronts Tripwires Everywhere in Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 09:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-12/biden-economic-agenda-confronts-tripwires-everywhere-in-congress?srnd=economics-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Debt ceiling, funding deadline complicates path after break\nDemocrats aim for early fall completion, but obstacles await\n\nThe central pieces of President Joe Biden’s $4.1 trillion economic agenda are ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-12/biden-economic-agenda-confronts-tripwires-everywhere-in-congress?srnd=economics-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.bloomberg.com/news/articles/2021-08-12/biden-economic-agenda-confronts-tripwires-everywhere-in-congress?srnd=economics-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154636497","content_text":"Debt ceiling, funding deadline complicates path after break\nDemocrats aim for early fall completion, but obstacles await\n\nThe central pieces of President Joe Biden’s $4.1 trillion economic agenda are now moving through Congress on a precarious two-track path that’s further complicated by a September showdown over the debt ceiling.\nFunding for the government will expire and the Treasury will approach the limit of its borrowing authority just as congressional Democrats try to make the administration’s massive infrastructure and social spending plans a reality.\nThe convergence will test the limits of how well House Speaker Nancy Pelosi and Senator Majority Leader Chuck Schumer can manage their narrow -- and often fractious -- majorities and Biden’s ability to bargain with dissenters.\nThe first part of Biden’s plan, infrastructure legislation with $550 billion in new spending, passed the Senate on a bipartisan basis. But the framework for a much larger plan -- a $3.5 trillion budget resolution opening the way to expansive spending on social programs paid for in part by taxes on the wealthy and corporations -- squeaked through on a straight party-line vote.\nHere’s what’s ahead for a process that could last through year-end:\nHouse Vote\nPelosi is briefly interrupting the chamber’s summer recess by calling lawmakers back to Washington on Aug. 23 to vote on the Senate’s budget resolution.\nShe needs near-unanimous Democratic support to adopt it against anticipated unified GOP opposition. The resolution is just an outline setting the parameters for an eventual budget bill and instructions for committees to draw up legislative text. It doesn’t require the president’s signature.\nFor now, the infrastructure bill is on hold. In a bow to demands by House progressives, Pelosi has vowed to wait until the Senate finishes the budget package to assure it addresses priorities on social programs and climate change. House Democrats may also want changes to the carefully negotiated infrastructure legislation.\nCommittee Work\nBoth chambers will then move to write precise policies and other language for the massive budget package, with the House likely to go first, predicts Zach Moller, a former Democratic Senate staffer who now works for Third Way, a centrist policy-research organization.\nHouse Democrats, ranging from top Pelosi lieutenants and powerful committee chairs to upstart progressives, are already signaling various changes they want to see in a final version of the Senate’s reconciliation package.\nThe Senate-passed resolution sets a nonbinding Sept. 15 deadline for committees in both chambers to submit proposals to their respective budget panels.\nThe Senate Finance Committee has jurisdiction over the heart of the package, including the tax hikes on the wealthy and corporations. Other committees can increase the deficit by about $1.75 trillion combined over a decade -- meaningup tohalf of Biden’s plan could be debt-financed.\nThere is no firm deadline on passage of the economic agenda, but Democrats keen on keeping their congressional majorities in the November 2022 midterm elections want the packages enacted this fall. That would allow voters time tofeelthe legislation’s effects and provide for the extension of popular pandemic-era benefits like the expanded child tax credit, which would otherwise end in December.\nFunding Showdown\nBy Sept. 30, lawmakers must reach bipartisan deals on unfinished regular government spending bills or on a stopgap bill to keep agencies running that would maintain current spending levels through at least October or early November.\nSuch a measure could carry language temporarily suspending the debt limit. But doing so could trigger a government shutdown. Republicans say Democrats must go it alone on the debt ceiling and want them to revise the budget resolution to allow them to pass a hike with a simple majority.\nSenate Democrats, however, insist for now on using the regular legislative process, which would require at least 10 Republicans to join them. Prospects for a bitter battle this fall have alreadystarted to impact short-term debt markets.\nHazards Ahead\nObstacles abound in the coming months. For one, House Democrats can afford just three defectors in a party-line vote. In the evenly divided Senate, unity is the only option.\nEven the House’s vote this month on the budget framework is no slam dunk. Party moderates, who want an immediate vote on the infrastructure package, could withhold their backing, stalling the measure.\nIn the Senate, not all Democrats are on board with the $3.5 trillion package, even though they all voted for the framework. Some, like Kyrsten Sinema of Arizona and Joe Manchin of West Virginia, say they’re uncomfortable with the price tag or the size of the tax hikes Biden has proposed to help pay for it.\nManchin has also said he disagrees with Democrats who want to target fossil fuels -- setting up tension for a key piece of the legislation.\nSchumer asserted Wednesday Democrats would ultimately unite, but he acknowledged it wouldn’t be easy.\nRepublicans will have ample opportunity to split Democrats and make their case that more taxes and spending will increase inflation and hurt the economy. Under special Senate rules they can force nearly unlimited amendments trying to strike individual provisions, potentially peeling off some Democrats in politically fraught votes.\nProcedural Pitfalls\nThe package will still have to clear a major procedural hurdle scrubbing it of anything deemed incidental to the federal budget.\nBiden’s $1.9 trillion Covid-19 relief package was shorn of a proposal for a $15-an-hour minimum wage via that process. Potential challenges in the $3.5 trillion plan include providing a path to citizenship for millions of immigrants.\nAll of this comes with long-term implications. In the short term, any misstep -- particularly on government spending and the debt ceiling -- could have large-scale reverberations in the market and the broader economy.\n“I am one who believes that neither party wins with government shut down or certainly government default so I lean toward being a little more optimistic that the latter will be avoided,” said former Senate Budget Committee Republican staff director Bill Hoagland, who’s now at the Bipartisan Policy Center. “But this is really an uncertain time.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895052395,"gmtCreate":1628696403517,"gmtModify":1676529825762,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585355301358956","idStr":"3585355301358956"},"themes":[],"htmlText":"Go, Wendy's! Love your spicy fried chicken! ?","listText":"Go, Wendy's! Love your spicy fried chicken! ?","text":"Go, Wendy's! Love your spicy fried chicken! ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/895052395","repostId":"2158104289","repostType":4,"repost":{"id":"2158104289","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628680630,"share":"https://ttm.financial/m/news/2158104289?lang=&edition=fundamental","pubTime":"2021-08-11 19:17","market":"us","language":"en","title":"Wendy's beats U.S. same-store sales estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2158104289","media":"Reuters","summary":"Aug 11 (Reuters) - Wendy's Co beat market estimates for U.S. same-store sales growth on Wednesday, a","content":"<p>Aug 11 (Reuters) - Wendy's Co beat market estimates for U.S. same-store sales growth on Wednesday, as customers returned to its restaurants after easing of dining restrictions put in place to check the spread of COVID-19.</p>\n<p>U.S. same-store sales for the second quarter rose 16.1%. Analysts were expecting a growth of 15.3%, according to IBES data from Refinitiv.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wendy's beats U.S. same-store sales estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWendy's beats U.S. same-store sales estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-11 19:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 11 (Reuters) - Wendy's Co beat market estimates for U.S. same-store sales growth on Wednesday, as customers returned to its restaurants after easing of dining restrictions put in place to check the spread of COVID-19.</p>\n<p>U.S. same-store sales for the second quarter rose 16.1%. Analysts were expecting a growth of 15.3%, according to IBES data from Refinitiv.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WEN":"温蒂汉堡"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158104289","content_text":"Aug 11 (Reuters) - Wendy's Co beat market estimates for U.S. same-store sales growth on Wednesday, as customers returned to its restaurants after easing of dining restrictions put in place to check the spread of COVID-19.\nU.S. same-store sales for the second quarter rose 16.1%. Analysts were expecting a growth of 15.3%, according to IBES data from Refinitiv.","news_type":1},"isVote":1,"tweetType":1,"viewCount":370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806736817,"gmtCreate":1627693245139,"gmtModify":1703494733767,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585355301358956","idStr":"3585355301358956"},"themes":[],"htmlText":"Interesting...","listText":"Interesting...","text":"Interesting...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/806736817","repostId":"2155001152","repostType":4,"repost":{"id":"2155001152","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627675228,"share":"https://ttm.financial/m/news/2155001152?lang=&edition=fundamental","pubTime":"2021-07-31 04:00","market":"us","language":"en","title":"Wall Street declines with Amazon; S&P 500 posts gains for month","url":"https://stock-news.laohu8.com/highlight/detail?id=2155001152","media":"Reuters","summary":"U.S. consumer spending rises in June, inflation increases . NEW YORK, July 30  - U.S. stocks fell on Friday with Amazon.com shares declining after the company forecast lower sales growth, but the S&P 500 still posted a sixth straight month of gains.Amazon.com Inc shares sank after it reported late on Thursday revenue for the second quarter that was shy of analysts' average estimate and said sales growth would ease in the next few quarters as customers ventured more outside the home.Shares of oth","content":"<ul>\n <li>Pinterest sinks on stalled U.S. user growth</li>\n <li>U.S. consumer spending rises in June, inflation increases (Updates to close)</li>\n</ul>\n<p>NEW YORK, July 30 (Reuters) - U.S. stocks fell on Friday with Amazon.com shares declining after the company forecast lower sales growth, but the S&amp;P 500 still posted a sixth straight month of gains.</p>\n<p>Amazon.com Inc shares sank after it reported late on Thursday revenue for the second quarter that was shy of analysts' average estimate and said sales growth would ease in the next few quarters as customers ventured more outside the home.</p>\n<p>Shares of other internet and tech giants that did well during the lockdowns of last year, including Google parent Alphabet Inc and <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc, were mostly lower.</p>\n<p>\"Overall earnings have been good. But Amazon ... and some of last year's winners are taking some of the air out of the market today,\" said Jake Dollarhide, chief executive officer of Longbow Asset Management in Tulsa, Oklahoma. \"This market has been driven by big tech and when tech does well, the market seems to go right along with it, and when it doesn't,\" it falls.</p>\n<p>Data on Friday showed U.S. consumer spending rose more than expected in June, although annual inflation accelerated further above the Federal Reserve's 2% target.</p>\n<p>Unofficially, the Dow Jones Industrial Average fell 146.36 points, or 0.42%, to 34,938.17, the S&amp;P 500 lost 23.58 points, or 0.53%, to 4,395.57 and the Nasdaq Composite dropped 101.51 points, or 0.69%, to 14,676.76.</p>\n<p>Strong earnings and the continued rebound in the U.S. economy have helped to support stocks this month, but the rapid spread of the Delta variant of the coronavirus and rising inflation have been concerns.</p>\n<p>\"There are still some distant jitters, whispers about the Delta variant, about cases rising, and I think some underlying worries about a slowdown of the reopenings and possible reversal,\" Dollarhide said.</p>\n<p>Also on the earnings front, Pampers maker Procter &amp; Gamble Co rose as it forecast higher core earnings for this year, and U.S.-listed shares of Canada's <a href=\"https://laohu8.com/S/QSR\">Restaurant Brands International Inc</a> jumped after the Burger King owner beat estimates for quarterly profit.</p>\n<p>Pinterest Inc, however, plunged after saying U.S. user growth was decelerating as people who used the platform for crafts and DIY projects during the height of the pandemic were stepping out more.</p>\n<p>Caterpillar Inc shares also fell, even though the company posted a rise in second-quarter adjusted profit on the back of a recovery in global economic activity.</p>\n<p>Results on the quarter overall have been much stronger than expected, with about 89% of the reports beating analysts' estimates on earnings, according to IBES data from Refinitiv. Earnings are now expected to have climbed 89.8% in the second quarter versus forecasts of 65.4% at the start of July. (Reporting by Caroline Valetkevitch in New York Additional reporting by Sagarika Jaisinghani in Bengaluru Editing by Arun Koyyur and Matthew Lewis)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street declines with Amazon; S&P 500 posts gains for month</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street declines with Amazon; S&P 500 posts gains for month\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-31 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Pinterest sinks on stalled U.S. user growth</li>\n <li>U.S. consumer spending rises in June, inflation increases (Updates to close)</li>\n</ul>\n<p>NEW YORK, July 30 (Reuters) - U.S. stocks fell on Friday with Amazon.com shares declining after the company forecast lower sales growth, but the S&amp;P 500 still posted a sixth straight month of gains.</p>\n<p>Amazon.com Inc shares sank after it reported late on Thursday revenue for the second quarter that was shy of analysts' average estimate and said sales growth would ease in the next few quarters as customers ventured more outside the home.</p>\n<p>Shares of other internet and tech giants that did well during the lockdowns of last year, including Google parent Alphabet Inc and <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc, were mostly lower.</p>\n<p>\"Overall earnings have been good. But Amazon ... and some of last year's winners are taking some of the air out of the market today,\" said Jake Dollarhide, chief executive officer of Longbow Asset Management in Tulsa, Oklahoma. \"This market has been driven by big tech and when tech does well, the market seems to go right along with it, and when it doesn't,\" it falls.</p>\n<p>Data on Friday showed U.S. consumer spending rose more than expected in June, although annual inflation accelerated further above the Federal Reserve's 2% target.</p>\n<p>Unofficially, the Dow Jones Industrial Average fell 146.36 points, or 0.42%, to 34,938.17, the S&amp;P 500 lost 23.58 points, or 0.53%, to 4,395.57 and the Nasdaq Composite dropped 101.51 points, or 0.69%, to 14,676.76.</p>\n<p>Strong earnings and the continued rebound in the U.S. economy have helped to support stocks this month, but the rapid spread of the Delta variant of the coronavirus and rising inflation have been concerns.</p>\n<p>\"There are still some distant jitters, whispers about the Delta variant, about cases rising, and I think some underlying worries about a slowdown of the reopenings and possible reversal,\" Dollarhide said.</p>\n<p>Also on the earnings front, Pampers maker Procter &amp; Gamble Co rose as it forecast higher core earnings for this year, and U.S.-listed shares of Canada's <a href=\"https://laohu8.com/S/QSR\">Restaurant Brands International Inc</a> jumped after the Burger King owner beat estimates for quarterly profit.</p>\n<p>Pinterest Inc, however, plunged after saying U.S. user growth was decelerating as people who used the platform for crafts and DIY projects during the height of the pandemic were stepping out more.</p>\n<p>Caterpillar Inc shares also fell, even though the company posted a rise in second-quarter adjusted profit on the back of a recovery in global economic activity.</p>\n<p>Results on the quarter overall have been much stronger than expected, with about 89% of the reports beating analysts' estimates on earnings, according to IBES data from Refinitiv. Earnings are now expected to have climbed 89.8% in the second quarter versus forecasts of 65.4% at the start of July. (Reporting by Caroline Valetkevitch in New York Additional reporting by Sagarika Jaisinghani in Bengaluru Editing by Arun Koyyur and Matthew Lewis)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","OEF":"标普100指数ETF-iShares","SPXU":"三倍做空标普500ETF","SH":"标普500反向ETF","SSO":"两倍做多标普500ETF","AMZN":"亚马逊",".SPX":"S&P 500 Index","SDS":"两倍做空标普500ETF","OEX":"标普100","SPY":"标普500ETF","IVV":"标普500指数ETF","COMP":"Compass, Inc.","CAT":"卡特彼勒","UPRO":"三倍做多标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155001152","content_text":"Pinterest sinks on stalled U.S. user growth\nU.S. consumer spending rises in June, inflation increases (Updates to close)\n\nNEW YORK, July 30 (Reuters) - U.S. stocks fell on Friday with Amazon.com shares declining after the company forecast lower sales growth, but the S&P 500 still posted a sixth straight month of gains.\nAmazon.com Inc shares sank after it reported late on Thursday revenue for the second quarter that was shy of analysts' average estimate and said sales growth would ease in the next few quarters as customers ventured more outside the home.\nShares of other internet and tech giants that did well during the lockdowns of last year, including Google parent Alphabet Inc and Facebook Inc, were mostly lower.\n\"Overall earnings have been good. But Amazon ... and some of last year's winners are taking some of the air out of the market today,\" said Jake Dollarhide, chief executive officer of Longbow Asset Management in Tulsa, Oklahoma. \"This market has been driven by big tech and when tech does well, the market seems to go right along with it, and when it doesn't,\" it falls.\nData on Friday showed U.S. consumer spending rose more than expected in June, although annual inflation accelerated further above the Federal Reserve's 2% target.\nUnofficially, the Dow Jones Industrial Average fell 146.36 points, or 0.42%, to 34,938.17, the S&P 500 lost 23.58 points, or 0.53%, to 4,395.57 and the Nasdaq Composite dropped 101.51 points, or 0.69%, to 14,676.76.\nStrong earnings and the continued rebound in the U.S. economy have helped to support stocks this month, but the rapid spread of the Delta variant of the coronavirus and rising inflation have been concerns.\n\"There are still some distant jitters, whispers about the Delta variant, about cases rising, and I think some underlying worries about a slowdown of the reopenings and possible reversal,\" Dollarhide said.\nAlso on the earnings front, Pampers maker Procter & Gamble Co rose as it forecast higher core earnings for this year, and U.S.-listed shares of Canada's Restaurant Brands International Inc jumped after the Burger King owner beat estimates for quarterly profit.\nPinterest Inc, however, plunged after saying U.S. user growth was decelerating as people who used the platform for crafts and DIY projects during the height of the pandemic were stepping out more.\nCaterpillar Inc shares also fell, even though the company posted a rise in second-quarter adjusted profit on the back of a recovery in global economic activity.\nResults on the quarter overall have been much stronger than expected, with about 89% of the reports beating analysts' estimates on earnings, according to IBES data from Refinitiv. Earnings are now expected to have climbed 89.8% in the second quarter versus forecasts of 65.4% at the start of July. (Reporting by Caroline Valetkevitch in New York Additional reporting by Sagarika Jaisinghani in Bengaluru Editing by Arun Koyyur and Matthew Lewis)","news_type":1},"isVote":1,"tweetType":1,"viewCount":376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806803264,"gmtCreate":1627645687758,"gmtModify":1703493986789,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585355301358956","idStr":"3585355301358956"},"themes":[],"htmlText":"):","listText":"):","text":"):","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/806803264","repostId":"1168057115","repostType":4,"isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":886223594,"gmtCreate":1631597007718,"gmtModify":1676530585842,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585355301358956","authorIdStr":"3585355301358956"},"themes":[],"htmlText":"This is a refreshing take on things!&nbsp;","listText":"This is a refreshing take on things!&nbsp;","text":"This is a refreshing take on things!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/886223594","repostId":"1141290411","repostType":4,"repost":{"id":"1141290411","kind":"news","pubTimestamp":1631591077,"share":"https://ttm.financial/m/news/1141290411?lang=&edition=fundamental","pubTime":"2021-09-14 11:44","market":"us","language":"en","title":"Here are two large tech stocks to avoid, according to Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=1141290411","media":"Marketwatch","summary":"There’s still some opportunity among large-cap internet stocks, but investors should steer clear of ","content":"<p>There’s still some opportunity among large-cap internet stocks, but investors should steer clear of two names, according to Goldman Sachs.</p>\n<p>Goldman’s Eric Sheridan initiated coverage of 17 larger-capitalization internet stocks late Sunday and assigned sell ratings to Airbnb Inc.ABNBand Twitter Inc.TWTRshares. Airbnb’s stock is off 2.8% in Monday trading, while Twitter’s is down 3.4%.</p>\n<p>While Sheridan expects that Airbnb will continue to outgrow the broader online travel industry over the next five years, he sees a negative risk-reward balance on the stock.</p>\n<p>Sheridan wrote that investors seem to have high conviction that Airbnb will benefit from a “new normal” for travel given the emergence of more flexible work/life structures, meaning that they would be able to travel more freely and spend more time at their destinations. But he’s “not yet convinced of that outcome having a high probability” and argues that significant investor optimism about this dynamic is already priced into Airbnb’s stock.</p>\n<p>He set a $132 price target on the stock, which changed hands just above $160 as of midday Monday.</p>\n<p>Sheridan also worries about the risk/reward trade-off on Twitter, writing that he thinks the advertising recovery is priced into the shares.</p>\n<p>Another key issue for Twitter is whether the company can successfully use new features like audio rooms, newsletters, and tip jars to boost engagement and monetization. Twitter has been increasing the pace of feature introductions recently after gaining a reputation for being slow on innovation, but “the probability of success of these platform evolutions remains an open question,” Sheridan wrote.</p>\n<p>He set a $60 price target for the stock, which recently changed hands at $59.44.</p>\n<p>Sheridan was more upbeat on other elements of the internet universe, assigning buy ratings to shares of Amazon.com Inc.&nbsp;,Facebook Inc.&nbsp;,Alphabet Inc.&nbsp;,Snap Inc.&nbsp;,Uber Technologies Inc.&nbsp;,Lyft Inc.&nbsp;,and Expedia Group Inc.</p>\n<p>He is neutral on shares of Pinterest Inc.&nbsp;,Chewy Inc.&nbsp;,Netflix Inc.&nbsp;,Peloton Interactive Inc.&nbsp;,Spotify Technology,Booking Holdings Inc.&nbsp;,and DoorDash Inc.&nbsp;</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here are two large tech stocks to avoid, according to Goldman Sachs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere are two large tech stocks to avoid, according to Goldman Sachs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-14 11:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/here-are-two-large-tech-stocks-to-avoid-according-to-goldman-sachs-11631550925?mod=newsviewer_click><strong>Marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There’s still some opportunity among large-cap internet stocks, but investors should steer clear of two names, according to Goldman Sachs.\nGoldman’s Eric Sheridan initiated coverage of 17 larger-...</p>\n\n<a href=\"https://www.marketwatch.com/story/here-are-two-large-tech-stocks-to-avoid-according-to-goldman-sachs-11631550925?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABNB":"爱彼迎","TWTR":"Twitter"},"source_url":"https://www.marketwatch.com/story/here-are-two-large-tech-stocks-to-avoid-according-to-goldman-sachs-11631550925?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1141290411","content_text":"There’s still some opportunity among large-cap internet stocks, but investors should steer clear of two names, according to Goldman Sachs.\nGoldman’s Eric Sheridan initiated coverage of 17 larger-capitalization internet stocks late Sunday and assigned sell ratings to Airbnb Inc.ABNBand Twitter Inc.TWTRshares. Airbnb’s stock is off 2.8% in Monday trading, while Twitter’s is down 3.4%.\nWhile Sheridan expects that Airbnb will continue to outgrow the broader online travel industry over the next five years, he sees a negative risk-reward balance on the stock.\nSheridan wrote that investors seem to have high conviction that Airbnb will benefit from a “new normal” for travel given the emergence of more flexible work/life structures, meaning that they would be able to travel more freely and spend more time at their destinations. But he’s “not yet convinced of that outcome having a high probability” and argues that significant investor optimism about this dynamic is already priced into Airbnb’s stock.\nHe set a $132 price target on the stock, which changed hands just above $160 as of midday Monday.\nSheridan also worries about the risk/reward trade-off on Twitter, writing that he thinks the advertising recovery is priced into the shares.\nAnother key issue for Twitter is whether the company can successfully use new features like audio rooms, newsletters, and tip jars to boost engagement and monetization. Twitter has been increasing the pace of feature introductions recently after gaining a reputation for being slow on innovation, but “the probability of success of these platform evolutions remains an open question,” Sheridan wrote.\nHe set a $60 price target for the stock, which recently changed hands at $59.44.\nSheridan was more upbeat on other elements of the internet universe, assigning buy ratings to shares of Amazon.com Inc. ,Facebook Inc. ,Alphabet Inc. ,Snap Inc. ,Uber Technologies Inc. ,Lyft Inc. ,and Expedia Group Inc.\nHe is neutral on shares of Pinterest Inc. ,Chewy Inc. ,Netflix Inc. ,Peloton Interactive Inc. ,Spotify Technology,Booking Holdings Inc. ,and DoorDash Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819351320,"gmtCreate":1630036862660,"gmtModify":1676530207284,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585355301358956","authorIdStr":"3585355301358956"},"themes":[],"htmlText":"Interesting read!","listText":"Interesting read!","text":"Interesting read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819351320","repostId":"1196717589","repostType":4,"repost":{"id":"1196717589","kind":"news","pubTimestamp":1630034074,"share":"https://ttm.financial/m/news/1196717589?lang=&edition=fundamental","pubTime":"2021-08-27 11:14","market":"us","language":"en","title":"Who Owns The Most AMC Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=1196717589","media":"Thestreet","summary":"Of all the things to consider before buying a stock, understanding who owns the company’s equity is ","content":"<p>Of all the things to consider before buying a stock, understanding who owns the company’s equity is rarely a top-of-mind factor. In the case of AMC, however, the story may be a little different.</p>\n<p>Today, Wall Street Memes looks at AMC stock’s ownership and explains why it could have an impact on how the company operates – and how the stock behaves.</p>\n<p><b>AMC largest holders</b></p>\n<p>According to data provided byYahoo Finance, AMC has a float of 513 million shares. Of the total, about 74% is owned by the public, 25% by institutions and 0.3% by insiders – directors, company's officers, and those with access to company information before it becomes public.</p>\n<p>Among institutions, Vanguard and Blackrock are the top holders, with 8% and 6% of the shares, respectively. Naturally, these firms turn their holdings into shares of ETF, which in turn can (and usually do) end up owned by more individual investors.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/03a5fac491fbf01869bb0f43310b2bc9\" tg-width=\"1200\" tg-height=\"966\" referrerpolicy=\"no-referrer\"><span>Figure 1: AMC stock ownership.ChartMill</span></p>\n<p>In May, AMC's previous largest shareholder, China's Dalian Wanda Group Co,sold30.4 million of its shares purchased in 2012 for roughly $430 million – funny enough, only days before AMC stock spiked from $14 to over $60 apiece. Currently, Wanda owns only 10,000 shares, representing a small $420,000 in market value.</p>\n<p>After the large Wanda sale, AMC's CEO Adam Aronrevealedthat no entity held an ownership stake above 10%.</p>\n<h3>Implications for the stock</h3>\n<p>A company whose ownership is widely distributed across the general public, as is the case of AMC, can benefit in a couple of ways. For instance, AMC can implement or change company policy without necessarily being aligned first with a handful of key shareholders.</p>\n<p>AMC’s ownership layout allowed for something curious to happen recently. CEO Adam Aron put to a vote theissuanceof 25 million new shares, which was then vetoed by a majority of AMC shareholders due to fears over a share price decline. Were AMC primarily owned by only a few, the polling would have likely not even taken place.</p>\n<p>In the end, the ownership structure allows AMC the flexibility to make its strategic decisions with certain independence – unless the management team chooses to consult with the broader base of individual investors more often.</p>\n<h3>In conclusion</h3>\n<p>AMC stock is owned, by and large, by retail investors – roughly speaking, the AMC ape community. Based on the latest shareholder count&nbsp;providedby AMC itself, the percentage of general public ownership is now greater than 80%, with each retail investor holding around 120 shares ($5,000) on average.</p>\n<p>Wall Street Memes believes that this is a good setup for AMC’s retail investors, as the fate of the company depends much less on the agenda of large institutions and a few insiders.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Who Owns The Most AMC Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWho Owns The Most AMC Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 11:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/amc/who-owns-the-most-amc-stock><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Of all the things to consider before buying a stock, understanding who owns the company’s equity is rarely a top-of-mind factor. In the case of AMC, however, the story may be a little different.\nToday...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/amc/who-owns-the-most-amc-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.thestreet.com/memestocks/amc/who-owns-the-most-amc-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196717589","content_text":"Of all the things to consider before buying a stock, understanding who owns the company’s equity is rarely a top-of-mind factor. In the case of AMC, however, the story may be a little different.\nToday, Wall Street Memes looks at AMC stock’s ownership and explains why it could have an impact on how the company operates – and how the stock behaves.\nAMC largest holders\nAccording to data provided byYahoo Finance, AMC has a float of 513 million shares. Of the total, about 74% is owned by the public, 25% by institutions and 0.3% by insiders – directors, company's officers, and those with access to company information before it becomes public.\nAmong institutions, Vanguard and Blackrock are the top holders, with 8% and 6% of the shares, respectively. Naturally, these firms turn their holdings into shares of ETF, which in turn can (and usually do) end up owned by more individual investors.\nFigure 1: AMC stock ownership.ChartMill\nIn May, AMC's previous largest shareholder, China's Dalian Wanda Group Co,sold30.4 million of its shares purchased in 2012 for roughly $430 million – funny enough, only days before AMC stock spiked from $14 to over $60 apiece. Currently, Wanda owns only 10,000 shares, representing a small $420,000 in market value.\nAfter the large Wanda sale, AMC's CEO Adam Aronrevealedthat no entity held an ownership stake above 10%.\nImplications for the stock\nA company whose ownership is widely distributed across the general public, as is the case of AMC, can benefit in a couple of ways. For instance, AMC can implement or change company policy without necessarily being aligned first with a handful of key shareholders.\nAMC’s ownership layout allowed for something curious to happen recently. CEO Adam Aron put to a vote theissuanceof 25 million new shares, which was then vetoed by a majority of AMC shareholders due to fears over a share price decline. Were AMC primarily owned by only a few, the polling would have likely not even taken place.\nIn the end, the ownership structure allows AMC the flexibility to make its strategic decisions with certain independence – unless the management team chooses to consult with the broader base of individual investors more often.\nIn conclusion\nAMC stock is owned, by and large, by retail investors – roughly speaking, the AMC ape community. Based on the latest shareholder count providedby AMC itself, the percentage of general public ownership is now greater than 80%, with each retail investor holding around 120 shares ($5,000) on average.\nWall Street Memes believes that this is a good setup for AMC’s retail investors, as the fate of the company depends much less on the agenda of large institutions and a few insiders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806736817,"gmtCreate":1627693245139,"gmtModify":1703494733767,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585355301358956","authorIdStr":"3585355301358956"},"themes":[],"htmlText":"Interesting...","listText":"Interesting...","text":"Interesting...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/806736817","repostId":"2155001152","repostType":4,"repost":{"id":"2155001152","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627675228,"share":"https://ttm.financial/m/news/2155001152?lang=&edition=fundamental","pubTime":"2021-07-31 04:00","market":"us","language":"en","title":"Wall Street declines with Amazon; S&P 500 posts gains for month","url":"https://stock-news.laohu8.com/highlight/detail?id=2155001152","media":"Reuters","summary":"U.S. consumer spending rises in June, inflation increases . NEW YORK, July 30  - U.S. stocks fell on Friday with Amazon.com shares declining after the company forecast lower sales growth, but the S&P 500 still posted a sixth straight month of gains.Amazon.com Inc shares sank after it reported late on Thursday revenue for the second quarter that was shy of analysts' average estimate and said sales growth would ease in the next few quarters as customers ventured more outside the home.Shares of oth","content":"<ul>\n <li>Pinterest sinks on stalled U.S. user growth</li>\n <li>U.S. consumer spending rises in June, inflation increases (Updates to close)</li>\n</ul>\n<p>NEW YORK, July 30 (Reuters) - U.S. stocks fell on Friday with Amazon.com shares declining after the company forecast lower sales growth, but the S&amp;P 500 still posted a sixth straight month of gains.</p>\n<p>Amazon.com Inc shares sank after it reported late on Thursday revenue for the second quarter that was shy of analysts' average estimate and said sales growth would ease in the next few quarters as customers ventured more outside the home.</p>\n<p>Shares of other internet and tech giants that did well during the lockdowns of last year, including Google parent Alphabet Inc and <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc, were mostly lower.</p>\n<p>\"Overall earnings have been good. But Amazon ... and some of last year's winners are taking some of the air out of the market today,\" said Jake Dollarhide, chief executive officer of Longbow Asset Management in Tulsa, Oklahoma. \"This market has been driven by big tech and when tech does well, the market seems to go right along with it, and when it doesn't,\" it falls.</p>\n<p>Data on Friday showed U.S. consumer spending rose more than expected in June, although annual inflation accelerated further above the Federal Reserve's 2% target.</p>\n<p>Unofficially, the Dow Jones Industrial Average fell 146.36 points, or 0.42%, to 34,938.17, the S&amp;P 500 lost 23.58 points, or 0.53%, to 4,395.57 and the Nasdaq Composite dropped 101.51 points, or 0.69%, to 14,676.76.</p>\n<p>Strong earnings and the continued rebound in the U.S. economy have helped to support stocks this month, but the rapid spread of the Delta variant of the coronavirus and rising inflation have been concerns.</p>\n<p>\"There are still some distant jitters, whispers about the Delta variant, about cases rising, and I think some underlying worries about a slowdown of the reopenings and possible reversal,\" Dollarhide said.</p>\n<p>Also on the earnings front, Pampers maker Procter &amp; Gamble Co rose as it forecast higher core earnings for this year, and U.S.-listed shares of Canada's <a href=\"https://laohu8.com/S/QSR\">Restaurant Brands International Inc</a> jumped after the Burger King owner beat estimates for quarterly profit.</p>\n<p>Pinterest Inc, however, plunged after saying U.S. user growth was decelerating as people who used the platform for crafts and DIY projects during the height of the pandemic were stepping out more.</p>\n<p>Caterpillar Inc shares also fell, even though the company posted a rise in second-quarter adjusted profit on the back of a recovery in global economic activity.</p>\n<p>Results on the quarter overall have been much stronger than expected, with about 89% of the reports beating analysts' estimates on earnings, according to IBES data from Refinitiv. Earnings are now expected to have climbed 89.8% in the second quarter versus forecasts of 65.4% at the start of July. (Reporting by Caroline Valetkevitch in New York Additional reporting by Sagarika Jaisinghani in Bengaluru Editing by Arun Koyyur and Matthew Lewis)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street declines with Amazon; S&P 500 posts gains for month</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street declines with Amazon; S&P 500 posts gains for month\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-31 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Pinterest sinks on stalled U.S. user growth</li>\n <li>U.S. consumer spending rises in June, inflation increases (Updates to close)</li>\n</ul>\n<p>NEW YORK, July 30 (Reuters) - U.S. stocks fell on Friday with Amazon.com shares declining after the company forecast lower sales growth, but the S&amp;P 500 still posted a sixth straight month of gains.</p>\n<p>Amazon.com Inc shares sank after it reported late on Thursday revenue for the second quarter that was shy of analysts' average estimate and said sales growth would ease in the next few quarters as customers ventured more outside the home.</p>\n<p>Shares of other internet and tech giants that did well during the lockdowns of last year, including Google parent Alphabet Inc and <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc, were mostly lower.</p>\n<p>\"Overall earnings have been good. But Amazon ... and some of last year's winners are taking some of the air out of the market today,\" said Jake Dollarhide, chief executive officer of Longbow Asset Management in Tulsa, Oklahoma. \"This market has been driven by big tech and when tech does well, the market seems to go right along with it, and when it doesn't,\" it falls.</p>\n<p>Data on Friday showed U.S. consumer spending rose more than expected in June, although annual inflation accelerated further above the Federal Reserve's 2% target.</p>\n<p>Unofficially, the Dow Jones Industrial Average fell 146.36 points, or 0.42%, to 34,938.17, the S&amp;P 500 lost 23.58 points, or 0.53%, to 4,395.57 and the Nasdaq Composite dropped 101.51 points, or 0.69%, to 14,676.76.</p>\n<p>Strong earnings and the continued rebound in the U.S. economy have helped to support stocks this month, but the rapid spread of the Delta variant of the coronavirus and rising inflation have been concerns.</p>\n<p>\"There are still some distant jitters, whispers about the Delta variant, about cases rising, and I think some underlying worries about a slowdown of the reopenings and possible reversal,\" Dollarhide said.</p>\n<p>Also on the earnings front, Pampers maker Procter &amp; Gamble Co rose as it forecast higher core earnings for this year, and U.S.-listed shares of Canada's <a href=\"https://laohu8.com/S/QSR\">Restaurant Brands International Inc</a> jumped after the Burger King owner beat estimates for quarterly profit.</p>\n<p>Pinterest Inc, however, plunged after saying U.S. user growth was decelerating as people who used the platform for crafts and DIY projects during the height of the pandemic were stepping out more.</p>\n<p>Caterpillar Inc shares also fell, even though the company posted a rise in second-quarter adjusted profit on the back of a recovery in global economic activity.</p>\n<p>Results on the quarter overall have been much stronger than expected, with about 89% of the reports beating analysts' estimates on earnings, according to IBES data from Refinitiv. Earnings are now expected to have climbed 89.8% in the second quarter versus forecasts of 65.4% at the start of July. (Reporting by Caroline Valetkevitch in New York Additional reporting by Sagarika Jaisinghani in Bengaluru Editing by Arun Koyyur and Matthew Lewis)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","OEF":"标普100指数ETF-iShares","SPXU":"三倍做空标普500ETF","SH":"标普500反向ETF","SSO":"两倍做多标普500ETF","AMZN":"亚马逊",".SPX":"S&P 500 Index","SDS":"两倍做空标普500ETF","OEX":"标普100","SPY":"标普500ETF","IVV":"标普500指数ETF","COMP":"Compass, Inc.","CAT":"卡特彼勒","UPRO":"三倍做多标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155001152","content_text":"Pinterest sinks on stalled U.S. user growth\nU.S. consumer spending rises in June, inflation increases (Updates to close)\n\nNEW YORK, July 30 (Reuters) - U.S. stocks fell on Friday with Amazon.com shares declining after the company forecast lower sales growth, but the S&P 500 still posted a sixth straight month of gains.\nAmazon.com Inc shares sank after it reported late on Thursday revenue for the second quarter that was shy of analysts' average estimate and said sales growth would ease in the next few quarters as customers ventured more outside the home.\nShares of other internet and tech giants that did well during the lockdowns of last year, including Google parent Alphabet Inc and Facebook Inc, were mostly lower.\n\"Overall earnings have been good. But Amazon ... and some of last year's winners are taking some of the air out of the market today,\" said Jake Dollarhide, chief executive officer of Longbow Asset Management in Tulsa, Oklahoma. \"This market has been driven by big tech and when tech does well, the market seems to go right along with it, and when it doesn't,\" it falls.\nData on Friday showed U.S. consumer spending rose more than expected in June, although annual inflation accelerated further above the Federal Reserve's 2% target.\nUnofficially, the Dow Jones Industrial Average fell 146.36 points, or 0.42%, to 34,938.17, the S&P 500 lost 23.58 points, or 0.53%, to 4,395.57 and the Nasdaq Composite dropped 101.51 points, or 0.69%, to 14,676.76.\nStrong earnings and the continued rebound in the U.S. economy have helped to support stocks this month, but the rapid spread of the Delta variant of the coronavirus and rising inflation have been concerns.\n\"There are still some distant jitters, whispers about the Delta variant, about cases rising, and I think some underlying worries about a slowdown of the reopenings and possible reversal,\" Dollarhide said.\nAlso on the earnings front, Pampers maker Procter & Gamble Co rose as it forecast higher core earnings for this year, and U.S.-listed shares of Canada's Restaurant Brands International Inc jumped after the Burger King owner beat estimates for quarterly profit.\nPinterest Inc, however, plunged after saying U.S. user growth was decelerating as people who used the platform for crafts and DIY projects during the height of the pandemic were stepping out more.\nCaterpillar Inc shares also fell, even though the company posted a rise in second-quarter adjusted profit on the back of a recovery in global economic activity.\nResults on the quarter overall have been much stronger than expected, with about 89% of the reports beating analysts' estimates on earnings, according to IBES data from Refinitiv. Earnings are now expected to have climbed 89.8% in the second quarter versus forecasts of 65.4% at the start of July. (Reporting by Caroline Valetkevitch in New York Additional reporting by Sagarika Jaisinghani in Bengaluru Editing by Arun Koyyur and Matthew Lewis)","news_type":1},"isVote":1,"tweetType":1,"viewCount":376,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894695728,"gmtCreate":1628820174064,"gmtModify":1676529865156,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585355301358956","authorIdStr":"3585355301358956"},"themes":[],"htmlText":"Hang in there! ??","listText":"Hang in there! ??","text":"Hang in there! ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894695728","repostId":"1154636497","repostType":4,"repost":{"id":"1154636497","kind":"news","pubTimestamp":1628816538,"share":"https://ttm.financial/m/news/1154636497?lang=&edition=fundamental","pubTime":"2021-08-13 09:02","market":"us","language":"en","title":"Biden Economic Agenda Confronts Tripwires Everywhere in Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=1154636497","media":"Bloomberg","summary":"Debt ceiling, funding deadline complicates path after break\nDemocrats aim for early fall completion,","content":"<ul>\n <li>Debt ceiling, funding deadline complicates path after break</li>\n <li>Democrats aim for early fall completion, but obstacles await</li>\n</ul>\n<p>The central pieces of President Joe Biden’s $4.1 trillion economic agenda are now moving through Congress on a precarious two-track path that’s further complicated by a September showdown over the debt ceiling.</p>\n<p>Funding for the government will expire and the Treasury will approach the limit of its borrowing authority just as congressional Democrats try to make the administration’s massive infrastructure and social spending plans a reality.</p>\n<p>The convergence will test the limits of how well House Speaker Nancy Pelosi and Senator Majority Leader Chuck Schumer can manage their narrow -- and often fractious -- majorities and Biden’s ability to bargain with dissenters.</p>\n<p>The first part of Biden’s plan, infrastructure legislation with $550 billion in new spending, passed the Senate on a bipartisan basis. But the framework for a much larger plan -- a $3.5 trillion budget resolution opening the way to expansive spending on social programs paid for in part by taxes on the wealthy and corporations -- squeaked through on a straight party-line vote.</p>\n<p>Here’s what’s ahead for a process that could last through year-end:</p>\n<p>House Vote</p>\n<p>Pelosi is briefly interrupting the chamber’s summer recess by calling lawmakers back to <a href=\"https://laohu8.com/S/WASH\">Washington</a> on Aug. 23 to vote on the Senate’s budget resolution.</p>\n<p>She needs near-unanimous Democratic support to adopt it against anticipated unified GOP opposition. The resolution is just an outline setting the parameters for an eventual budget bill and instructions for committees to draw up legislative text. It doesn’t require the president’s signature.</p>\n<p>For now, the infrastructure bill is on hold. In a bow to demands by House progressives, Pelosi has vowed to wait until the Senate finishes the budget package to assure it addresses priorities on social programs and climate change. House Democrats may also want changes to the carefully negotiated infrastructure legislation.</p>\n<p>Committee Work</p>\n<p>Both chambers will then move to write precise policies and other language for the massive budget package, with the House likely to go first, predicts Zach Moller, a former Democratic Senate staffer who now works for Third Way, a centrist policy-research organization.</p>\n<p>House Democrats, ranging from top Pelosi lieutenants and powerful committee chairs to upstart progressives, are already signaling various changes they want to see in a final version of the Senate’s reconciliation package.</p>\n<p>The Senate-passed resolution sets a nonbinding Sept. 15 deadline for committees in both chambers to submit proposals to their respective budget panels.</p>\n<p>The Senate Finance Committee has jurisdiction over the heart of the package, including the tax hikes on the wealthy and corporations. Other committees can increase the deficit by about $1.75 trillion combined over a decade -- meaningup tohalf of Biden’s plan could be debt-financed.</p>\n<p>There is no firm deadline on passage of the economic agenda, but Democrats keen on keeping their congressional majorities in the November 2022 midterm elections want the packages enacted this fall. That would allow voters time tofeelthe legislation’s effects and provide for the extension of popular pandemic-era benefits like the expanded child tax credit, which would otherwise end in December.</p>\n<p>Funding Showdown</p>\n<p>By Sept. 30, lawmakers must reach bipartisan deals on unfinished regular government spending bills or on a stopgap bill to keep agencies running that would maintain current spending levels through at least October or early November.</p>\n<p>Such a measure could carry language temporarily suspending the debt limit. But doing so could trigger a government shutdown. Republicans say Democrats must go it alone on the debt ceiling and want them to revise the budget resolution to allow them to pass a hike with a simple majority.</p>\n<p>Senate Democrats, however, insist for now on using the regular legislative process, which would require at least 10 Republicans to join them. Prospects for a bitter battle this fall have alreadystarted to impact short-term debt markets.</p>\n<p>Hazards Ahead</p>\n<p>Obstacles abound in the coming months. For <a href=\"https://laohu8.com/S/AONE.U\">one</a>, House Democrats can afford just three defectors in a party-line vote. In the evenly divided Senate, unity is the only option.</p>\n<p>Even the House’s vote this month on the budget framework is no slam dunk. Party moderates, who want an immediate vote on the infrastructure package, could withhold their backing, stalling the measure.</p>\n<p>In the Senate, not all Democrats are on board with the $3.5 trillion package, even though they all voted for the framework. Some, like Kyrsten Sinema of Arizona and Joe Manchin of <a href=\"https://laohu8.com/S/WSTC\">West</a> Virginia, say they’re uncomfortable with the price tag or the size of the tax hikes Biden has proposed to help pay for it.</p>\n<p>Manchin has also said he disagrees with Democrats who want to target fossil fuels -- setting up tension for a key piece of the legislation.</p>\n<p>Schumer asserted Wednesday Democrats would ultimately unite, but he acknowledged it wouldn’t be easy.</p>\n<p>Republicans will have ample opportunity to split Democrats and make their case that more taxes and spending will increase inflation and hurt the economy. Under special Senate rules they can force nearly unlimited amendments trying to strike individual provisions, potentially peeling off some Democrats in politically fraught votes.</p>\n<p>Procedural Pitfalls</p>\n<p>The package will still have to clear a major procedural hurdle scrubbing it of anything deemed incidental to the federal budget.</p>\n<p>Biden’s $1.9 trillion Covid-19 relief package was shorn of a proposal for a $15-an-hour minimum wage via that process. Potential challenges in the $3.5 trillion plan include providing a path to citizenship for millions of immigrants.</p>\n<p>All of this comes with long-term implications. In the short term, any misstep -- particularly on government spending and the debt ceiling -- could have large-scale reverberations in the market and the broader economy.</p>\n<p>“I am one who believes that neither party wins with government shut down or certainly government default so I lean toward being a little more optimistic that the latter will be avoided,” said former Senate Budget Committee Republican staff director Bill Hoagland, who’s now at the Bipartisan Policy Center. “But this is really an uncertain time.”</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biden Economic Agenda Confronts Tripwires Everywhere in Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiden Economic Agenda Confronts Tripwires Everywhere in Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-13 09:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-12/biden-economic-agenda-confronts-tripwires-everywhere-in-congress?srnd=economics-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Debt ceiling, funding deadline complicates path after break\nDemocrats aim for early fall completion, but obstacles await\n\nThe central pieces of President Joe Biden’s $4.1 trillion economic agenda are ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-12/biden-economic-agenda-confronts-tripwires-everywhere-in-congress?srnd=economics-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.bloomberg.com/news/articles/2021-08-12/biden-economic-agenda-confronts-tripwires-everywhere-in-congress?srnd=economics-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154636497","content_text":"Debt ceiling, funding deadline complicates path after break\nDemocrats aim for early fall completion, but obstacles await\n\nThe central pieces of President Joe Biden’s $4.1 trillion economic agenda are now moving through Congress on a precarious two-track path that’s further complicated by a September showdown over the debt ceiling.\nFunding for the government will expire and the Treasury will approach the limit of its borrowing authority just as congressional Democrats try to make the administration’s massive infrastructure and social spending plans a reality.\nThe convergence will test the limits of how well House Speaker Nancy Pelosi and Senator Majority Leader Chuck Schumer can manage their narrow -- and often fractious -- majorities and Biden’s ability to bargain with dissenters.\nThe first part of Biden’s plan, infrastructure legislation with $550 billion in new spending, passed the Senate on a bipartisan basis. But the framework for a much larger plan -- a $3.5 trillion budget resolution opening the way to expansive spending on social programs paid for in part by taxes on the wealthy and corporations -- squeaked through on a straight party-line vote.\nHere’s what’s ahead for a process that could last through year-end:\nHouse Vote\nPelosi is briefly interrupting the chamber’s summer recess by calling lawmakers back to Washington on Aug. 23 to vote on the Senate’s budget resolution.\nShe needs near-unanimous Democratic support to adopt it against anticipated unified GOP opposition. The resolution is just an outline setting the parameters for an eventual budget bill and instructions for committees to draw up legislative text. It doesn’t require the president’s signature.\nFor now, the infrastructure bill is on hold. In a bow to demands by House progressives, Pelosi has vowed to wait until the Senate finishes the budget package to assure it addresses priorities on social programs and climate change. House Democrats may also want changes to the carefully negotiated infrastructure legislation.\nCommittee Work\nBoth chambers will then move to write precise policies and other language for the massive budget package, with the House likely to go first, predicts Zach Moller, a former Democratic Senate staffer who now works for Third Way, a centrist policy-research organization.\nHouse Democrats, ranging from top Pelosi lieutenants and powerful committee chairs to upstart progressives, are already signaling various changes they want to see in a final version of the Senate’s reconciliation package.\nThe Senate-passed resolution sets a nonbinding Sept. 15 deadline for committees in both chambers to submit proposals to their respective budget panels.\nThe Senate Finance Committee has jurisdiction over the heart of the package, including the tax hikes on the wealthy and corporations. Other committees can increase the deficit by about $1.75 trillion combined over a decade -- meaningup tohalf of Biden’s plan could be debt-financed.\nThere is no firm deadline on passage of the economic agenda, but Democrats keen on keeping their congressional majorities in the November 2022 midterm elections want the packages enacted this fall. That would allow voters time tofeelthe legislation’s effects and provide for the extension of popular pandemic-era benefits like the expanded child tax credit, which would otherwise end in December.\nFunding Showdown\nBy Sept. 30, lawmakers must reach bipartisan deals on unfinished regular government spending bills or on a stopgap bill to keep agencies running that would maintain current spending levels through at least October or early November.\nSuch a measure could carry language temporarily suspending the debt limit. But doing so could trigger a government shutdown. Republicans say Democrats must go it alone on the debt ceiling and want them to revise the budget resolution to allow them to pass a hike with a simple majority.\nSenate Democrats, however, insist for now on using the regular legislative process, which would require at least 10 Republicans to join them. Prospects for a bitter battle this fall have alreadystarted to impact short-term debt markets.\nHazards Ahead\nObstacles abound in the coming months. For one, House Democrats can afford just three defectors in a party-line vote. In the evenly divided Senate, unity is the only option.\nEven the House’s vote this month on the budget framework is no slam dunk. Party moderates, who want an immediate vote on the infrastructure package, could withhold their backing, stalling the measure.\nIn the Senate, not all Democrats are on board with the $3.5 trillion package, even though they all voted for the framework. Some, like Kyrsten Sinema of Arizona and Joe Manchin of West Virginia, say they’re uncomfortable with the price tag or the size of the tax hikes Biden has proposed to help pay for it.\nManchin has also said he disagrees with Democrats who want to target fossil fuels -- setting up tension for a key piece of the legislation.\nSchumer asserted Wednesday Democrats would ultimately unite, but he acknowledged it wouldn’t be easy.\nRepublicans will have ample opportunity to split Democrats and make their case that more taxes and spending will increase inflation and hurt the economy. Under special Senate rules they can force nearly unlimited amendments trying to strike individual provisions, potentially peeling off some Democrats in politically fraught votes.\nProcedural Pitfalls\nThe package will still have to clear a major procedural hurdle scrubbing it of anything deemed incidental to the federal budget.\nBiden’s $1.9 trillion Covid-19 relief package was shorn of a proposal for a $15-an-hour minimum wage via that process. Potential challenges in the $3.5 trillion plan include providing a path to citizenship for millions of immigrants.\nAll of this comes with long-term implications. In the short term, any misstep -- particularly on government spending and the debt ceiling -- could have large-scale reverberations in the market and the broader economy.\n“I am one who believes that neither party wins with government shut down or certainly government default so I lean toward being a little more optimistic that the latter will be avoided,” said former Senate Budget Committee Republican staff director Bill Hoagland, who’s now at the Bipartisan Policy Center. “But this is really an uncertain time.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":806803264,"gmtCreate":1627645687758,"gmtModify":1703493986789,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585355301358956","authorIdStr":"3585355301358956"},"themes":[],"htmlText":"):","listText":"):","text":"):","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/806803264","repostId":"1168057115","repostType":4,"isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836412336,"gmtCreate":1629513985825,"gmtModify":1676530062934,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585355301358956","authorIdStr":"3585355301358956"},"themes":[],"htmlText":"Ooooooh...","listText":"Ooooooh...","text":"Ooooooh...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836412336","repostId":"2160714914","repostType":4,"repost":{"id":"2160714914","kind":"highlight","pubTimestamp":1629464330,"share":"https://ttm.financial/m/news/2160714914?lang=&edition=fundamental","pubTime":"2021-08-20 20:58","market":"us","language":"en","title":"Here's What Recent News From the FDA Means for AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=2160714914","media":"Motley Fool","summary":"Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost.","content":"<p>Last month, the <a href=\"https://laohu8.com/S/CSII\">Cardiovascular</a> and Renal Drugs Advisory Committee (CRDAC) of the U.S. Food and Drug Administration (FDA) denied <b><a href=\"https://laohu8.com/S/AZN\">AstraZeneca PLC</a> </b>(NASDAQ:&nbsp;AZN) and <b><a href=\"https://laohu8.com/S/FGEN\">FibroGen</a></b>'s (NASDAQ:&nbsp;FGEN) drug roxadustat for the treatment of anemia in patients with chronic kidney disease (CKD).</p>\n<p>This was in both non-dialysis-dependent (NDD) patients (by a 13-to-1 vote) and dialysis-dependent (DD) patients (a 12-to-2 vote).</p>\n<p>AstraZeneca and FibroGen are collaborating to develop and commercialize roxadustat for the treatment of anemia related to CKD in areas including the U.S., Australia and <a href=\"https://laohu8.com/S/NGD\">New</a> Zealand, <a href=\"https://laohu8.com/S/CAAS\">China</a>, and Southeast Asia. Meanwhile, FibroGen and <b><a href=\"https://laohu8.com/S/ALPMY\">Astellas Pharma, Inc.</a> </b>(OTC:&nbsp;ALPMY) are developing and commercializing roxadustat for the treatment of CKD-related anemia in Japan, Europe, the Middle East, and South Africa.</p>\n<p>AstraZeneca and FibroGen received a complete response letter from the FDA earlier this month, requesting another safety trial for both the NDD and DD patient populations. Let's break down the implications for roxadustat's future, and what that might mean for AstraZeneca.</p>\n<p><img src=\"https://static.tigerbbs.com/bb06b77b879f31a4dff027154b6d049e\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h2>The logic behind the panel's decision</h2>\n<p>It's worth discussing what led to this decisive rejection. While FDA staffer Dr. Saleh Ayache noted that \"the FDA believes the Applicant has provided substantial evidence of efficacy,\" CRDAC chair Dr. Julia Lewis indicated that \"there are concerns over adverse safety.\"</p>\n<p>To this point, FibroGen announced in April that the disclosed safety analyses for roxadustat from November 2019 in the treatment of anemia of CKD were incorrect.</p>\n<p>In the original presentation of the study's data, the risk of non-dialysis-dependent (NDD) patients taking roxadustat and experiencing major adverse cardiac events (MACE) over the duration of the Phase 3 trial was 8% higher than for patients taking placebo. The revised data showed a slight increase in that risk, to 10% more than placebo, adding to the overall risk profile of the drug and working against the odds of a potential FDA approval.</p>\n<p>The risk of dialysis-dependent (DD) patients taking roxadustat and suffering from MACE was initially thought to be 4% lower than for those taking peer drug epoetin-alfa (Epogen, developed by <b><a href=\"https://laohu8.com/S/AMGN\">Amgen</a></b> and <b>Johnson and Johnson</b>). However, the revised data showed that the probability of DD patients taking roxadustat and enduring MACE was actually 2% higher than Epogen. This meant that AstraZeneca and FibroGen were no longer able to claim that roxadustat was safer than Epogen in DD patients, which was a claim that previously gave roxadustat an advantage over Epogen.</p>\n<p>The risk of incident dialysis (ID) patients who have been on dialysis for four months or less taking roxadustat and experiencing MACE was initially thought to be 30% lower compared to Epogen, but the corrected data showed that the risk of MACE complications was only reduced by 18%. While roxadustat remains safer than Epogen in ID patients, the advantage is far less than what was thought to be the case initially.</p>\n<p>AstraZeneca and FibroGen will now consider funding an additional clinical trial to continue pursuing FDA approval for roxadustat to treat CKD-related anemia. The trial would test whether a lower dosage of roxadustat would improve its safety profile, possibly allowing FDA approval later down the road assuming efficacy remained steady.</p>\n<h2>Roxadustat is down, but not out</h2>\n<p>Even with CRDAC's request for another clinical trial, there's reason to be optimistic. Roxadustat was approved by China's <a href=\"https://laohu8.com/S/NHLD\">National</a> Medical Products Administration (NMPA) to be marketed for treating anemia in CKD patients, both on dialysis and not on dialysis, in August 2019. And while roxadustat has been on the market in China for less than two years, the drug has made a great deal of progress in the country during that time.</p>\n<p>According to FibroGen, hospital listings (a list or formulary of all the drugs available for prescription from a particular hospital) at the end of the second quarter of 2021 \"represented approximately 81% of the CKD anemia market opportunity in China,\" compared with 74% in the prior quarter. In other words, hospital offerings of the drug in China continue to expand. Roxadustat's continued penetration in the China market generated $92 million in revenue for AstraZeneca during the first half of 2021, with an acceleration from $40 million in Q1 to $52 million in <a href=\"https://laohu8.com/S/QTWO\">Q2</a>.</p>\n<p>Even if AstraZeneca isn't ultimately able to secure FDA approval to treat the 6 million patients in the <a href=\"https://laohu8.com/S/UBNK\">United</a> States with anemia related to CKD, the Chinese market alone could be enough to more than double sales of the drug from now till the end of the decade.</p>\n<p>This is supported by a combination of growing adoption of roxadustat within China, as well as the fact that Research and Markets expects the CKD anemia market to grow 3.4% annually, to reach global sales of $6.6 billion by 2029.</p>\n<p>The research company anticipates that the Chinese market alone will reach $1 billion in revenue by 2029, so I can see a clear path to about $400 million by the end of the decade for AstraZeneca.</p>\n<h2>AstraZeneca will be fine regardless of FDA approval</h2>\n<p>While it remains to be seen whether roxadustat will someday be approved by the FDA, AstraZeneca isn't depending on the approval as much as FibroGen.</p>\n<p>This is because unlike FibroGen, which is highly dependent on roxadustat (all of its product revenue came from roxadustat in the first half of this year), AstraZeneca is a diversified large-cap pharma company.</p>\n<p>AstraZeneca owns three rapidly growing oncology drugs (Tagrisso, Imfinzi, and Lynparza), which grew their total first-half revenue 25.3% year over year from $3.79 billion in H1 2020 to $4.75 billion in H1 2021.</p>\n<p>AstraZeneca's completed acquisition of <a href=\"https://laohu8.com/S/ALXN\">Alexion Pharmaceuticals</a> last month only further solidified the company's growth potential. That's because Alexion's top three drugs (Soliris, Ultomiris, and Strensiq) saw their net revenue soar 20.4% from $4.88 billion in 2019 to $5.87 billion in 2020.</p>\n<p>AstraZeneca is trading at around 16 times next year's average analyst EPS (earnings per share) estimate of $3.71, which is still a solid value, given the 20% annual earnings growth that analysts expect over the next five years.</p>\n<p>Those who already own AstraZeneca and those considering adding it to their portfolios can both be confident that the company's future is solid regardless of roxadustat's U.S. status.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's What Recent News From the FDA Means for AstraZeneca</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's What Recent News From the FDA Means for AstraZeneca\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-20 20:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/20/heres-what-recent-fda-news-means-for-astrazeneca/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last month, the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) of the U.S. Food and Drug Administration (FDA) denied AstraZeneca PLC (NASDAQ: AZN) and FibroGen's (NASDAQ: FGEN) drug ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/20/heres-what-recent-fda-news-means-for-astrazeneca/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","FGEN":"FibroGen, Inc","ALPMY":"Astellas Pharma, Inc."},"source_url":"https://www.fool.com/investing/2021/08/20/heres-what-recent-fda-news-means-for-astrazeneca/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160714914","content_text":"Last month, the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) of the U.S. Food and Drug Administration (FDA) denied AstraZeneca PLC (NASDAQ: AZN) and FibroGen's (NASDAQ: FGEN) drug roxadustat for the treatment of anemia in patients with chronic kidney disease (CKD).\nThis was in both non-dialysis-dependent (NDD) patients (by a 13-to-1 vote) and dialysis-dependent (DD) patients (a 12-to-2 vote).\nAstraZeneca and FibroGen are collaborating to develop and commercialize roxadustat for the treatment of anemia related to CKD in areas including the U.S., Australia and New Zealand, China, and Southeast Asia. Meanwhile, FibroGen and Astellas Pharma, Inc. (OTC: ALPMY) are developing and commercializing roxadustat for the treatment of CKD-related anemia in Japan, Europe, the Middle East, and South Africa.\nAstraZeneca and FibroGen received a complete response letter from the FDA earlier this month, requesting another safety trial for both the NDD and DD patient populations. Let's break down the implications for roxadustat's future, and what that might mean for AstraZeneca.\n\nImage source: Getty Images.\nThe logic behind the panel's decision\nIt's worth discussing what led to this decisive rejection. While FDA staffer Dr. Saleh Ayache noted that \"the FDA believes the Applicant has provided substantial evidence of efficacy,\" CRDAC chair Dr. Julia Lewis indicated that \"there are concerns over adverse safety.\"\nTo this point, FibroGen announced in April that the disclosed safety analyses for roxadustat from November 2019 in the treatment of anemia of CKD were incorrect.\nIn the original presentation of the study's data, the risk of non-dialysis-dependent (NDD) patients taking roxadustat and experiencing major adverse cardiac events (MACE) over the duration of the Phase 3 trial was 8% higher than for patients taking placebo. The revised data showed a slight increase in that risk, to 10% more than placebo, adding to the overall risk profile of the drug and working against the odds of a potential FDA approval.\nThe risk of dialysis-dependent (DD) patients taking roxadustat and suffering from MACE was initially thought to be 4% lower than for those taking peer drug epoetin-alfa (Epogen, developed by Amgen and Johnson and Johnson). However, the revised data showed that the probability of DD patients taking roxadustat and enduring MACE was actually 2% higher than Epogen. This meant that AstraZeneca and FibroGen were no longer able to claim that roxadustat was safer than Epogen in DD patients, which was a claim that previously gave roxadustat an advantage over Epogen.\nThe risk of incident dialysis (ID) patients who have been on dialysis for four months or less taking roxadustat and experiencing MACE was initially thought to be 30% lower compared to Epogen, but the corrected data showed that the risk of MACE complications was only reduced by 18%. While roxadustat remains safer than Epogen in ID patients, the advantage is far less than what was thought to be the case initially.\nAstraZeneca and FibroGen will now consider funding an additional clinical trial to continue pursuing FDA approval for roxadustat to treat CKD-related anemia. The trial would test whether a lower dosage of roxadustat would improve its safety profile, possibly allowing FDA approval later down the road assuming efficacy remained steady.\nRoxadustat is down, but not out\nEven with CRDAC's request for another clinical trial, there's reason to be optimistic. Roxadustat was approved by China's National Medical Products Administration (NMPA) to be marketed for treating anemia in CKD patients, both on dialysis and not on dialysis, in August 2019. And while roxadustat has been on the market in China for less than two years, the drug has made a great deal of progress in the country during that time.\nAccording to FibroGen, hospital listings (a list or formulary of all the drugs available for prescription from a particular hospital) at the end of the second quarter of 2021 \"represented approximately 81% of the CKD anemia market opportunity in China,\" compared with 74% in the prior quarter. In other words, hospital offerings of the drug in China continue to expand. Roxadustat's continued penetration in the China market generated $92 million in revenue for AstraZeneca during the first half of 2021, with an acceleration from $40 million in Q1 to $52 million in Q2.\nEven if AstraZeneca isn't ultimately able to secure FDA approval to treat the 6 million patients in the United States with anemia related to CKD, the Chinese market alone could be enough to more than double sales of the drug from now till the end of the decade.\nThis is supported by a combination of growing adoption of roxadustat within China, as well as the fact that Research and Markets expects the CKD anemia market to grow 3.4% annually, to reach global sales of $6.6 billion by 2029.\nThe research company anticipates that the Chinese market alone will reach $1 billion in revenue by 2029, so I can see a clear path to about $400 million by the end of the decade for AstraZeneca.\nAstraZeneca will be fine regardless of FDA approval\nWhile it remains to be seen whether roxadustat will someday be approved by the FDA, AstraZeneca isn't depending on the approval as much as FibroGen.\nThis is because unlike FibroGen, which is highly dependent on roxadustat (all of its product revenue came from roxadustat in the first half of this year), AstraZeneca is a diversified large-cap pharma company.\nAstraZeneca owns three rapidly growing oncology drugs (Tagrisso, Imfinzi, and Lynparza), which grew their total first-half revenue 25.3% year over year from $3.79 billion in H1 2020 to $4.75 billion in H1 2021.\nAstraZeneca's completed acquisition of Alexion Pharmaceuticals last month only further solidified the company's growth potential. That's because Alexion's top three drugs (Soliris, Ultomiris, and Strensiq) saw their net revenue soar 20.4% from $4.88 billion in 2019 to $5.87 billion in 2020.\nAstraZeneca is trading at around 16 times next year's average analyst EPS (earnings per share) estimate of $3.71, which is still a solid value, given the 20% annual earnings growth that analysts expect over the next five years.\nThose who already own AstraZeneca and those considering adding it to their portfolios can both be confident that the company's future is solid regardless of roxadustat's U.S. status.","news_type":1},"isVote":1,"tweetType":1,"viewCount":380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831435376,"gmtCreate":1629339745095,"gmtModify":1676530008058,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585355301358956","authorIdStr":"3585355301358956"},"themes":[],"htmlText":"Uh-oh...","listText":"Uh-oh...","text":"Uh-oh...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831435376","repostId":"1129521206","repostType":4,"isVote":1,"tweetType":1,"viewCount":435,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895052395,"gmtCreate":1628696403517,"gmtModify":1676529825762,"author":{"id":"3585355301358956","authorId":"3585355301358956","name":"LimJY","avatar":"https://static.tigerbbs.com/640bdfbc1dbc49a353bf0b462ddfd6fb","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585355301358956","authorIdStr":"3585355301358956"},"themes":[],"htmlText":"Go, Wendy's! Love your spicy fried chicken! ?","listText":"Go, Wendy's! Love your spicy fried chicken! ?","text":"Go, Wendy's! Love your spicy fried chicken! ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/895052395","repostId":"2158104289","repostType":4,"repost":{"id":"2158104289","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628680630,"share":"https://ttm.financial/m/news/2158104289?lang=&edition=fundamental","pubTime":"2021-08-11 19:17","market":"us","language":"en","title":"Wendy's beats U.S. same-store sales estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2158104289","media":"Reuters","summary":"Aug 11 (Reuters) - Wendy's Co beat market estimates for U.S. same-store sales growth on Wednesday, a","content":"<p>Aug 11 (Reuters) - Wendy's Co beat market estimates for U.S. same-store sales growth on Wednesday, as customers returned to its restaurants after easing of dining restrictions put in place to check the spread of COVID-19.</p>\n<p>U.S. same-store sales for the second quarter rose 16.1%. Analysts were expecting a growth of 15.3%, according to IBES data from Refinitiv.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wendy's beats U.S. same-store sales estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWendy's beats U.S. same-store sales estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-11 19:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 11 (Reuters) - Wendy's Co beat market estimates for U.S. same-store sales growth on Wednesday, as customers returned to its restaurants after easing of dining restrictions put in place to check the spread of COVID-19.</p>\n<p>U.S. same-store sales for the second quarter rose 16.1%. Analysts were expecting a growth of 15.3%, according to IBES data from Refinitiv.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WEN":"温蒂汉堡"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158104289","content_text":"Aug 11 (Reuters) - Wendy's Co beat market estimates for U.S. same-store sales growth on Wednesday, as customers returned to its restaurants after easing of dining restrictions put in place to check the spread of COVID-19.\nU.S. same-store sales for the second quarter rose 16.1%. Analysts were expecting a growth of 15.3%, according to IBES data from Refinitiv.","news_type":1},"isVote":1,"tweetType":1,"viewCount":370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}